Hopace Tablets contain Ramipril 1.25 mg, 2.5 mg, 5 mg, or 10 mg.

Hopace Tablets contain Ramipril, a long-acting angiotensin-converting enzyme (ACE) inhibitor that effectively lowers blood pressure by reducing the formation of angiotensin II. This results in vasodilation, reduced aldosterone secretion, decreased cardiac workload, and improved cardiovascular function. In addition to treating hypertension, Hopace provides cardiovascular protection by reducing the risk of myocardial infarction, stroke, and cardiovascular death, while also offering renal protection in patients with non-diabetic nephropathy.

Hopace Tablets are indicated for the treatment of hypertension, congestive heart failure, and patients following myocardial infarction. They are also indicated to reduce the risk of myocardial infarction, stroke, and cardiovascular death in high-risk cardiovascular and diabetic patients. In addition, Hopace is indicated for the treatment of overt or incipient non-diabetic glomerular nephropathy.

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By reducing angiotensin II levels, Ramipril decreases vasoconstriction and aldosterone secretion, resulting in reduced peripheral vascular resistance, improved blood flow, and lower blood pressure. The reduction in aldosterone also decreases sodium and water retention, reducing cardiac workload and improving cardiac efficiency. These actions provide effective blood pressure control while offering significant cardiovascular and renal protection.

The recommended dosage of Hopace Tablets depends on the clinical indication and individual patient response. For hypertension, treatment is generally initiated with 1.25 mg once daily, with gradual dose adjustment according to blood pressure response up to a maximum of 20 mg daily. For reduction of myocardial infarction, stroke, or cardiovascular death, the recommended regimen is 2.5 mg once daily for one week, followed by 5 mg once daily for three weeks, and then increased as tolerated to a maintenance dose of 10 mg once daily. For heart failure following myocardial infarction, the recommended starting dose is 2.5 mg twice daily, which may be gradually increased to 5 mg twice daily based on patient tolerance and clinical response.

Hopace Tablets are contraindicated in patients with a history of hypersensitivity to Ramipril or any component of the formulation, previous angioedema associated with ACE inhibitor therapy, hereditary or idiopathic angioedema, and in patients receiving concomitant aliskiren therapy who have diabetes or renal impairment with a glomerular filtration rate below 60 mL/min/1.73 m².